Navigation Links
European Company NovaSecta Joins First Chinese CRO Service Alliance for Drug Discovery Solutions
Date:2/18/2008

SHANGHAI, China, Feb. 18 /Xinhua-PRNewswire/ -- Today, NovaSecta, Sundia Meditech and HD BioSciences announced their strategic alliance to provide drug discovery solutions for European pharmaceutical and biotech companies. This alliance brings together the high quality scientific capabilities of Sundia and HD BioSciences with NovaSecta's extensive client base and unique understanding of European mid-sized pharmaceutical and biotech companies.

To date, the rapidly-growing Chinese Discovery CRO phenomenon has been largely driven by global and US "Big Pharma" and "Big Biotech" companies -- both as consumers of CRO services and as sources of highly-experienced returnee scientists to China. European pharmaceutical and biotech companies now need to make use of the scientific skills, creative talent pool, flexible resourcing and cost-effectiveness that many global Big Pharmas already take for granted in China.

NovaSecta's business is centered on providing smaller to mid-sized pharmaceutical and biotech companies the scale advantages that Big Pharmas enjoy while allowing them to remain independent, fast and flexible. This alliance is therefore a natural step in NovaSecta's evolution as an R&D services company. "We selected Sundia Meditech and HD BioSciences as our alliance partners based on their professionalism and track record in repeatedly delivering drug discovery solutions to their US and multi-national clients. Combining the skills and demonstrated drug discovery track record of their scientific teams with the expertise of European drug discovery scientists will surely lead to faster and more efficient generation of high quality drug candidates" said Robert Thong and John Rountree, NovaSecta's co- founders and Managing Directors.

Sundia Meditech, United PharmaTech, and HD BioSciences entered into a CRO Service Alliance in May 2007. In the following months, Sundia and United merged into one company, a first successful merger of China's CRO industry. The initial alliance was formed to quickly and successfully expand into the complete range of CRO services to fit the increased demands from clients worldwide while maintaining high quality and efficiency and minimizing cost. "We believe that by extending our alliance to include NovaSecta, we will bring significant benefits to European customers, so we look forward to working with NovaSecta and more European clients," said Dr. Xiaochuan Wang, Sundia Meditech's founder and CEO and Dr. Xuehai Tan, HD BioSciences' founder and CEO.

About NovaSecta (http://www.novasecta.com )

NovaSecta is a specialist R&D service provider for smaller to mid-sized pharmaceutical and biotech companies ('MidPharmas'). Since its founding in early 2003, NovaSecta has built a unique network of relationships with MidPharmas in Europe and a deep understanding of how these companies manage and develop their R&D capabilities. NovaSecta's current business is originating and managing collaborations for MidPharmas; to date these have included a multi-company R&D program, product/project licensing and acquisitions, and scientific R&D collaborations.

About Sundia Meditech (http://www.sundia.com )

Sundia MediTech was founded in Shanghai in 2004 by veterans of the US biopharmaceutical industry, and is now a leading CRO company in China. The founding team has talent and track record in organic synthesis, medicinal chemistry, drug design and discovery, process chemistry, cGMP API production, in vitro/vivo PK research, and business and IP management. Sundia has successfully worked with over 50 companies world-wide, and provides services in custom synthesis, library production, lead optimization (PD and PK), scale up, pre-clinical studies, cGMP API production and pharmaceutical development.

About HD BioSciences (http://www.hdbiosciences.com )

HD BioSciences, based in Shanghai, is one of the leading biology CRO companies in China. The company is known for its expertise in assay development, high-throughput screening (HTS), hit-to-lead solutions, high- throughput compound profiling, and natural compound-based lead identification. The company's proprietary assays and screening platforms give it a competitive edge in drug lead discovery services and in providing value to its partners and clients from pharmaceutical and biotech companies world-wide.


'/>"/>
SOURCE Sundia Meditech
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. USC and second sight announce European clinical trial for Argus II retinal implant
2. Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents
3. AGA Medical Corporation Receives European CE Mark Approval for the AMPLATZER(R) Duct Occluder II
4. European Commission gives grant to investigate transatlantic oversight of nanotech
5. Vasogens Research Published in European Journal of Neuroscience
6. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
7. Statement on the Release of the European Food Safety Assessment on the Safety of Food Derived From Clones and Their Offspring in the Food Supply
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. GeneSeek Selects the British Midlands as Base for New UK/European Operations
10. First European Patient Treated in CABERNET Trial With Novel Treatment for Wet AMD
11. Millennium Research Group Offers New Marketrack Service that Tracks European Dental Implant Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... first-ever genomics analysis platform specifically designed for life science researchers to analyze ... pioneering researcher Rosalind Franklin, who made a major contribution to the discovery ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... today it will be hosting a Webinar titled, “Pathology is going digital. Is ... , on digital pathology adoption best practices and how Proscia improves lab economics ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh ... orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of ... SBT-100 is able to cross the cell membrane and bind intracellular STAT3 and ...
(Date:10/10/2017)... firm Parks Associates announced today that Tom Kerber , ... Meeting , October 11 in Scottsdale, Arizona . Kerber ... smart safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and the introduction ...
Breaking Biology Technology:
(Date:4/18/2017)... 2017  Socionext Inc., a global expert in SoC-based imaging and ... the M820, which features the company,s hybrid codec technology. A demonstration ... Probe, Inc., will be showcased during the upcoming Medtec Japan at ... the Las Vegas Convention Center April 24-27. ... Click here for an ...
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... grow at a CAGR of 30.37% during the period 2017-2021. ... prepared based on an in-depth market analysis with inputs from industry ... over the coming years. The report also includes a discussion of ...
(Date:4/5/2017)... Today HYPR Corp. , leading innovator ... of the HYPR platform is officially FIDO® Certified ... architecture that empowers biometric authentication across Fortune 500 enterprises ... over 15 million users across the financial services industry, ... product suites and physical access represent a growing portion ...
Breaking Biology News(10 mins):